Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

COVID-19

Free Subscription Articles published in Antiviral Res Retrieve available abstracts of 225 articles: HTML format

Single Articles

February 2026
1. ZHANG T, Wang ZL, Li XY, Luo RH, et al
   Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m(6)A enzymatic activity.
   Antiviral Res. 2026 Feb 19:106376. doi: 10.1016/j.antiviral.2026.106376.
   PubMed     Abstract available
   
   
   
2. LIU Q, Tang B, Xuan X, Wang H, et al
   The potential of leritrelvir repositioning for the treatment of coxsackievirus B4 and common enterovirus infections.
   Antiviral Res. 2026 Feb 16:106367. doi: 10.1016/j.antiviral.2026.106367.
   PubMed     Abstract available
   
   
   
3. TOSELLI F, Jacobs S, Scheers E, Jacobs T, et al
   Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.
   Antiviral Res. 2026 Feb 9:106363. doi: 10.1016/j.antiviral.2026.106363.
   PubMed     Abstract available
   
   
   January 2026
4. YURGELONIS I, Rai DK, Li Z, Washington B, et al
   Analysis of Ibuzatrelvir's Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance Mutations.
   Antiviral Res. 2026 Jan 30:106352. doi: 10.1016/j.antiviral.2026.106352.
   PubMed     Abstract available
   
   
   
5. HEDSKOG C, Rodriguez L, Hu Y, Li J, et al
   SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19.
   Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351.
   PubMed     Abstract available
   
   
   December 2025
6. RODRIGUEZ L, Hu Y, Li J, Han D, et al
   SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19.
   Antiviral Res. 2025 Dec 29:106339. doi: 10.1016/j.antiviral.2025.106339.
   PubMed     Abstract available
   
   
   November 2025
7. DENG X, Zou J, Liang Z, Ren P, et al
   A Dual-Reporter HCoV-OC43 for Coronavirus Biology and Countermeasure Development.
   Antiviral Res. 2025 Nov 3:106306. doi: 10.1016/j.antiviral.2025.106306.
   PubMed     Abstract available
   
   
   October 2025
8. SCHRELL L, Scheibner D, Dickmanns A, Stegmann KM, et al
   Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication.
   Antiviral Res. 2025 Oct 3:106286. doi: 10.1016/j.antiviral.2025.106286.
   PubMed     Abstract available
   
   
   September 2025
9. ZHU C, Wang Z, Pan Z, Mai X, et al
   DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection.
   Antiviral Res. 2025 Sep 3:106269. doi: 10.1016/j.antiviral.2025.106269.
   PubMed     Abstract available
   
   
   
10. TASHIMA R, Kuroda T, Nobori H, Miyagawa S, et al
    Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamsters.
    Antiviral Res. 2025 Sep 2:106270. doi: 10.1016/j.antiviral.2025.106270.
    PubMed     Abstract available
    
    
    August 2025
11. ICHIKAWA T, Tamura T, Nao N, Suzuki H, et al
    Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases.
    Antiviral Res. 2025;242:106264.
    PubMed     Abstract available
    
    
    
12. BI W, Zhu T, Xu Y, Chen Y, et al
    An engineered chimeric ACE2-HR2 peptide exhibits potent and broad-spectrum activity against SARS-CoV-2 variants.
    Antiviral Res. 2025;242:106265.
    PubMed     Abstract available
    
    
    
13. TERATAKE Y, Okamura T, Ishizaka Y
    SMAD5 phosphorylation by ALK1 is modulated by the interaction of the spike protein of SARS-CoV-2 and angiotensin-converting enzyme 2.
    Antiviral Res. 2025;242:106261.
    PubMed     Abstract available
    
    
    
14. GOLDIN K, Brackney B, Lutterman T, Williamson BN, et al
    Dexamethasone treatment does not alter mortality but reduces pulmonary pathology in Nipah virus-infected Syrian hamsters.
    Antiviral Res. 2025;242:106263.
    PubMed     Abstract available
    
    
    
15. LEI F, Shu J, Xia C, Lei Y, et al
    Viral determinants of cis- and trans-cleavage by SARS-CoV-2 Nsp3 and an on-off reporter for monitoring intracellular protease activity.
    Antiviral Res. 2025;242:106262.
    PubMed     Abstract available
    
    
    
16. YAO G, Shi X, Jiang H, Duan A, et al
    Design, synthesis, and biological evaluation of novel 6-aminoalkyl- and 7-heteroaryl substituted 7-deazapurine nucleoside analogs against SARS-CoV-2 Replication.
    Antiviral Res. 2025 Aug 1:106246. doi: 10.1016/j.antiviral.2025.106246.
    PubMed     Abstract available
    
    
    July 2025
17. AL KRAD D, Stegmann KM, Dickmanns A, Kumar P, et al
    The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication.
    Antiviral Res. 2025 Jul 29:106247. doi: 10.1016/j.antiviral.2025.106247.
    PubMed     Abstract available
    
    
    
18. PATEL D, De R, Azadi N, Lee S, et al
    Discovery of broad-spectrum antivirals targeting viral proteases using in silico structural modeling and cellular analysis.
    Antiviral Res. 2025;241:106245.
    PubMed     Abstract available
    
    
    
19. LEBEDIN M, Petrovsky N, Tabynov K, Tabynov K, et al
    SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody.
    Antiviral Res. 2025;241:106235.
    PubMed     Abstract available
    
    
    June 2025
20. HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al
    Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.
    Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217.
    PubMed     Abstract available
    
    
    
21. CHANG CW, Oswal N, Murugan M, Goldgirsh K, et al
    A novel cellular tool for screening human pan-coronavirus antivirals.
    Antiviral Res. 2025 Jun 10:106212. doi: 10.1016/j.antiviral.2025.106212.
    PubMed     Abstract available
    
    
    
22. MALUNE P, Esposito F, Tramontano E
    Unveiling SARS-CoV-2's heart: role, structure and inhibition of SARS-CoV-2 RNA-dependent RNA polymerase.
    Antiviral Res. 2025 Jun 3:106208. doi: 10.1016/j.antiviral.2025.106208.
    PubMed     Abstract available
    
    
    April 2025
23. MARTIN HJ, Hossain MA, Wellnitz J, Kelestemur E, et al
    Chemical arsenal for helicase Hunters: Striking the toughest targets in antiviral research.
    Antiviral Res. 2025;239:106184.
    PubMed     Abstract available
    
    
    
24. KELLY JA, Aida-Ficken V, McMullan LK, Chatterjee P, et al
    Mechanisms of action of repurposed Ebola virus antivirals - the roles of phospholipidosis and cholesterol homeostasis.
    Antiviral Res. 2025 Apr 15:106167. doi: 10.1016/j.antiviral.2025.106167.
    PubMed     Abstract available
    
    
    March 2025
25. ZHU Y, Gao Z, Feng X, Hu Y, et al
    Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials.
    Antiviral Res. 2025;237:106154.
    PubMed     Abstract available
    
    
    
26. XU M, Zhang Z, Sun Y, Mai H, et al
    Corrigendum to "IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility" [Antiv. Res. (2025) 106082].
    Antiviral Res. 2025 Mar 20:106146. doi: 10.1016/j.antiviral.2025.106146.
    PubMed    
    
    
    
27. SAFIRIYU AA, Hussain A, Dewangan N, Kasle G, et al
    The fusion peptide of the spike protein S2 domain may be a mimetic analog of beta-coronaviruses and serve as a novel virus-host membrane fusion inhibitor.
    Antiviral Res. 2025 Mar 16:106144. doi: 10.1016/j.antiviral.2025.106144.
    PubMed     Abstract available
    
    
    
28. PADEY B, Droillard C, Duliere V, Fouret J, et al
    Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2.
    Antiviral Res. 2025 Mar 4:106138. doi: 10.1016/j.antiviral.2025.106138.
    PubMed     Abstract available
    
    
    February 2025
29. BRUN J, Arman BY, Hill ML, Kiappes JL, et al
    Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.
    Antiviral Res. 2025 Feb 23:106123. doi: 10.1016/j.antiviral.2025.106123.
    PubMed     Abstract available
    
    
    
30. ZIAN D, Iaconis D, Nenci S, Crusco A, et al
    The Efficiency of High-Throughput Screening (HTS) and in-silico data analysis during medical emergencies: identification of effective antiviral 3CLpro inhibitors.
    Antiviral Res. 2025 Feb 18:106119. doi: 10.1016/j.antiviral.2025.106119.
    PubMed     Abstract available
    
    
    
31. INOUE A, Ichikawa T, Wada D, Maruyama S, et al
    M49L and other drug resistance mutations emerging in individuals after administration of ensitrelvir in Japanese clinical settings.
    Antiviral Res. 2025;236:106118.
    PubMed     Abstract available
    
    
    
32. SCHREIBER A, Ludwig S
    Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?
    Antiviral Res. 2025;235:106101.
    PubMed     Abstract available
    
    
    
33. CHUTIWITOONCHAI N, Akkarawongsapat R, Chantawarin S, Jiarpinitnun C, et al
    Antiviral effect of pinostrobin, a bioactive constituent of Boesenbergia rotunda, against porcine epidemic diarrhea virus.
    Antiviral Res. 2025;234:106073.
    PubMed     Abstract available
    
    
    January 2025
34. UEHARA T, Yotsuyanagi H, Ohmagari N, Doi Y, et al
    Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CL(pro) detected in the SCORPIO-SR phase 3 trial.
    Antiviral Res. 2025 Jan 30:106097. doi: 10.1016/j.antiviral.2025.106097.
    PubMed     Abstract available
    
    
    
35. WU Q, Wu H, Hu Y, Zheng X, et al
    Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.
    Antiviral Res. 2025 Jan 24:106092. doi: 10.1016/j.antiviral.2025.106092.
    PubMed     Abstract available
    
    
    
36. XU M, Zhang Z, Sun Y, Mai H, et al
    IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility.
    Antiviral Res. 2025 Jan 17:106082. doi: 10.1016/j.antiviral.2025.106082.
    PubMed     Abstract available
    
    
    December 2024
37. GAO M, Zhang Z, Yao G, Zhang L, et al
    Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.
    Antiviral Res. 2024 Dec 30:106060. doi: 10.1016/j.antiviral.2024.106060.
    PubMed     Abstract available
    
    
    
38. MERCURI FA, Anderson GP, Miller BE, Demaison C, et al
    Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections.
    Antiviral Res. 2024 Dec 27:106063. doi: 10.1016/j.antiviral.2024.106063.
    PubMed     Abstract available
    
    
    
39. SHANNON A, Canard B
    Nucleotide analogues and mpox: Repurposing the repurposable.
    Antiviral Res. 2024;234:106057.
    PubMed     Abstract available
    
    
    
40. WANG B, Xia H, Peng BH, Choi EJ, et al
    Pellino-1, a therapeutic target for control of SARS-CoV-2 infection and disease severity.
    Antiviral Res. 2024;233:106059.
    PubMed     Abstract available
    
    
    
41. SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
    Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4'-fluorouridine.
    Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
    PubMed     Abstract available
    
    
    
42. WELCH SR, Bilello JP, Carter K, Delang L, et al
    Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.
    Antiviral Res. 2024;232:106037.
    PubMed     Abstract available
    
    
    November 2024
43. GENG X, Zhu Y, Gao Y, Chong H, et al
    Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.
    Antiviral Res. 2024 Nov 23:106042. doi: 10.1016/j.antiviral.2024.106042.
    PubMed     Abstract available
    
    
    
44. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
    Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
    Antiviral Res. 2024;232:106041.
    PubMed     Abstract available
    
    
    
45. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
    Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
    Antiviral Res. 2024;232:106038.
    PubMed     Abstract available
    
    
    
46. SASAKI J, Sato A, Sasaki M, Okabe I, et al
    X-206 exhibits broad-spectrum anti-beta-coronavirus activity, covering SARS-CoV-2 variants and drug-resistant isolates.
    Antiviral Res. 2024 Nov 19:106039. doi: 10.1016/j.antiviral.2024.106039.
    PubMed     Abstract available
    
    
    
47. SAMA B, Selisko B, Falcou C, Fattorini V, et al
    The effects of Remdesivir's functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
    Antiviral Res. 2024 Nov 5:106034. doi: 10.1016/j.antiviral.2024.106034.
    PubMed     Abstract available
    
    
    October 2024
48. NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al
    Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.
    Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026.
    PubMed     Abstract available
    
    
    
49. LO CW, Kariv O, Hao C, Gammeltoft KA, et al
    Replication Capacity and Susceptibility of Nirmatrelvir-Resistant Mutants to Next-Generation Mpro Inhibitors in a SARS-CoV-2 Replicon System.
    Antiviral Res. 2024 Oct 16:106022. doi: 10.1016/j.antiviral.2024.106022.
    PubMed     Abstract available
    
    
    
50. ZHOU J, Sun P, Wang Y, Shi Y, et al
    Design and biological evaluation of candidate drugs against zoonotic porcine deltacoronavirus (PDCoV).
    Antiviral Res. 2024;231:106019.
    PubMed     Abstract available
    
    
    September 2024
51. VAN DER HORST D, Carter-Timofte ME, Danneels A, Silva da Costa L, et al
    Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses.
    Antiviral Res. 2024;231:106012.
    PubMed     Abstract available
    
    
    
52. HERRMANN A, Gege C, Wangen C, Wagner S, et al
    Orally Bioavailable RORgamma/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity.
    Antiviral Res. 2024 Sep 19:106008. doi: 10.1016/j.antiviral.2024.106008.
    PubMed     Abstract available
    
    
    
53. KUMAR P, Zhang X, Shaha R, Kschischo M, et al
    Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis.
    Antiviral Res. 2024;231:106006.
    PubMed     Abstract available
    
    
    
54. DO TND, Abdelnabi R, Boda B, Constant S, et al
    The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
    Antiviral Res. 2024 Sep 3:105994. doi: 10.1016/j.antiviral.2024.105994.
    PubMed     Abstract available
    
    
    August 2024
55. YAMASAKI M, Saso W, Yamamoto T, Sato M, et al
    Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA.
    Antiviral Res. 2024;230:105992.
    PubMed     Abstract available
    
    
    
56. LEE P, Kim J, Oh H, Kim CU, et al
    Coronavirus Nucleocapsid-based Vaccine Provides Partial Protection against Hetero-species Coronavirus in Murine Models.
    Antiviral Res. 2024 Aug 22:105991. doi: 10.1016/j.antiviral.2024.105991.
    PubMed     Abstract available
    
    
    
57. CONG Y, Dixit S, Perry DL, Huzella LM, et al
    Characterization of therapeutic antibodies efficacy against multiple SARS-CoV-2 variants in the hamster model.
    Antiviral Res. 2024 Aug 13:105987. doi: 10.1016/j.antiviral.2024.105987.
    PubMed     Abstract available
    
    
    
58. KEISER PT, Zhang W, Ricca M, Wacquiez A, et al
    Amidino-Rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis.
    Antiviral Res. 2024 Aug 6:105976. doi: 10.1016/j.antiviral.2024.105976.
    PubMed     Abstract available
    
    
    July 2024
59. KONISHI K, Kusakabe S, Kawaguchi N, Shishido T, et al
    beta-d-N(4)-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus.
    Antiviral Res. 2024 Jul 30:105977. doi: 10.1016/j.antiviral.2024.105977.
    PubMed     Abstract available
    
    
    
60. ROSALES R, McGovern BL, Rodriguez ML, Leiva-Rebollo R, et al
    Nirmatrelvir and Molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 Omicron subvariants.
    Antiviral Res. 2024 Jul 25:105970. doi: 10.1016/j.antiviral.2024.105970.
    PubMed     Abstract available
    
    
    
61. RAUCH S, Costacurta F, Schoppe H, Peng JY, et al
    Highly specific SARS-CoV-2 main protease (M(pro)) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system.
    Antiviral Res. 2024 Jul 23:105969. doi: 10.1016/j.antiviral.2024.105969.
    PubMed     Abstract available
    
    
    
62. OLIVEIRA EH, Monteleone-Cassiano AC, Tavares L, Santos JC, et al
    A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19.
    Antiviral Res. 2024;229:105968.
    PubMed     Abstract available
    
    
    
63. YOTSUYANAGI H, Ohmagari N, Doi Y, Yamato M, et al
    Prevention of Post COVID-19 Condition by Early Treatment with Ensitrelvir in the Phase 3 SCORPIO-SR Trial.
    Antiviral Res. 2024 Jul 5:105958. doi: 10.1016/j.antiviral.2024.105958.
    PubMed     Abstract available
    
    
    
64. JI J, Tang T, Zhu M, Wu Z, et al
    Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.
    Antiviral Res. 2024 Jul 2:105954. doi: 10.1016/j.antiviral.2024.105954.
    PubMed     Abstract available
    
    
    June 2024
65. WILLIAMS N, Silva F, Schmolke M
    Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy.
    Antiviral Res. 2024 Jun 28:105951. doi: 10.1016/j.antiviral.2024.105951.
    PubMed     Abstract available
    
    
    
66. DANIELS A, Padariya M, Fletcher S, Ball K, et al
    Molecules targeting a novel homotrimer cavity of Spike protein attenuate replication of SARS-CoV-2.
    Antiviral Res. 2024;228:105949.
    PubMed     Abstract available
    
    
    
67. BALIGA-GIL A, Soszynska-Jozwiak M, Ruszkowska A, Szczesniak I, et al
    Targeting sgRNA N secondary structure as a way of inhibiting SARS-CoV-2 replication.
    Antiviral Res. 2024 Jun 24:105946. doi: 10.1016/j.antiviral.2024.105946.
    PubMed     Abstract available
    
    
    
68. POTTER JA, Aitken A, Yang L, Hill J, et al
    HEX17(Neumifil): an intranasal respiratory biotherapeutic with broad-acting antiviral activity.
    Antiviral Res. 2024 Jun 22:105945. doi: 10.1016/j.antiviral.2024.105945.
    PubMed     Abstract available
    
    
    
69. LIU X, Zheng M, Zhang H, Feng B, et al
    Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-CoV-2 PLpro.
    Antiviral Res. 2024 Jun 22:105944. doi: 10.1016/j.antiviral.2024.105944.
    PubMed     Abstract available
    
    
    
70. DICKEY TH, Salinas ND, Patel P, Orr-Gonzalez S, et al
    RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination.
    Antiviral Res. 2024 Jun 18:105937. doi: 10.1016/j.antiviral.2024.105937.
    PubMed     Abstract available
    
    
    May 2024
71. VAN LOY B, Stevaert A, Naesens L
    The coronavirus nsp15 endoribonuclease: a puzzling protein and pertinent antiviral drug target.
    Antiviral Res. 2024 May 31:105921. doi: 10.1016/j.antiviral.2024.105921.
    PubMed     Abstract available
    
    
    
72. LE UNP, Chang YJ, Lu CH, Chen Y, et al
    Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Antiviral Res. 2024;227:105920.
    PubMed     Abstract available
    
    
    
73. LIANG Y, Xiao W, Peng Y, Zhang S, et al
    Development of Nanoparticle Vaccines Utilizing Designed Fc-Binding Homo-oligomers and RBD-Fc of SARS-CoV-2.
    Antiviral Res. 2024 May 21:105917. doi: 10.1016/j.antiviral.2024.105917.
    PubMed     Abstract available
    
    
    
74. HUANG J, Wang W, Li H, Bai Y, et al
    Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
    Antiviral Res. 2024;227:105905.
    PubMed     Abstract available
    
    
    
75. PANDEY K, Acharya A, Pal D, Jain P, et al
    SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.
    Antiviral Res. 2024;227:105904.
    PubMed     Abstract available
    
    
    
76. SALGADO-BENVINDO C, Tas A, Zevenhoven-Dobbe JC, van der Meer Y, et al
    Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: a versatile and practical infection model for antiviral research and beyond.
    Antiviral Res. 2024 May 7:105903. doi: 10.1016/j.antiviral.2024.105903.
    PubMed     Abstract available
    
    
    April 2024
77. LIU X, Wang Y, Sun L, Xiao G, et al
    Screening and optimization of shark nanobodies against SARS-CoV-2 Spike RBD.
    Antiviral Res. 2024 Apr 29:105898. doi: 10.1016/j.antiviral.2024.105898.
    PubMed     Abstract available
    
    
    
78. ARDUINO I, Francese R, Civra A, Feyles E, et al
    Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry.
    Antiviral Res. 2024;226:105897.
    PubMed     Abstract available
    
    
    
79. AMERATUNGA R, Jordan A, Lehnert K, Leung E, et al
    SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
    Antiviral Res. 2024 Apr 25:105894. doi: 10.1016/j.antiviral.2024.105894.
    PubMed     Abstract available
    
    
    
80. GLITSCHER M, Benz NI, Sabino C, Murra RO, et al
    Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
    Antiviral Res. 2024;226:105891.
    PubMed     Abstract available
    
    
    
81. TOLKSDORF B, Heinze J, Niemeyer D, Rohrs V, et al
    Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
    Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879.
    PubMed     Abstract available
    
    
    March 2024
82. KHATUA K, Alugubelli YR, Yang KS, Vulupala VR, et al
    Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Antiviral Res. 2024;225:105874.
    PubMed     Abstract available
    
    
    
83. SINIAVIN AE, Gushchin VA, Shastina NS, Darnotuk ES, et al
    New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871.
    PubMed     Abstract available
    
    
    
84. PEREZ-VARGAS J, Lemieux G, Thompson CAH, Desilets A, et al
    Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
    Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869.
    PubMed     Abstract available
    
    
    
85. DE MEYER A, Meuleman P
    Preclinical animal models to evaluate therapeutic antiviral antibodies.
    Antiviral Res. 2024 Mar 26:105843. doi: 10.1016/j.antiviral.2024.105843.
    PubMed     Abstract available
    
    
    
86. MOON C, Porges E, Roberts A, Bacon J, et al
    A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication.
    Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859.
    PubMed     Abstract available
    
    
    
87. BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
    SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential.
    Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
    PubMed     Abstract available
    
    
    
88. WANG W, Wang S, Meng X, Zhao Y, et al
    A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
    Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854.
    PubMed     Abstract available
    
    
    
89. KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al
    Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
    Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856.
    PubMed     Abstract available
    
    
    
90. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
    The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
    Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
    PubMed     Abstract available
    
    
    February 2024
91. NOBORI H, Baba K, Kuroda T, Baba K, et al
    Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Antiviral Res. 2024;224:105852.
    PubMed     Abstract available
    
    
    
92. LI H, Sun M, Lei F, Liu J, et al
    Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3?C?L protease as a potential candidate against SARS-cov-2 infection.
    Antiviral Res. 2024 Feb 24:105841. doi: 10.1016/j.antiviral.2024.105841.
    PubMed     Abstract available
    
    
    
93. BIGOTTI MG, Klein K, Gan ES, Anastasina M, et al
    The alpha-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses.
    Antiviral Res. 2024 Feb 20:105837. doi: 10.1016/j.antiviral.2024.105837.
    PubMed     Abstract available
    
    
    
94. SANTOS-FERREIRA N, Van Dycke J, Chiu W, Neyts J, et al
    Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids.
    Antiviral Res. 2024;223:105839.
    PubMed     Abstract available
    
    
    
95. TAM EH, Peng Y, Yan Cheah MX, Yan C, et al
    Neutralizing antibodies to block viral entry and for identification of entry inhibitors.
    Antiviral Res. 2024 Feb 16:105834. doi: 10.1016/j.antiviral.2024.105834.
    PubMed     Abstract available
    
    
    
96. SINHA D, Yaugel-Novoa M, Waeckel L, Paul S, et al
    Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses.
    Antiviral Res. 2024 Feb 6:105823. doi: 10.1016/j.antiviral.2024.105823.
    PubMed     Abstract available
    
    
    
97. WANG Y, Liu Y, Wang J, Zhang M, et al
    An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses.
    Antiviral Res. 2024;223:105825.
    PubMed     Abstract available
    
    
    
98. JIAO Z, Wang P, Hu X, Chen Y, et al
    Feline infectious peritonitis virus ORF7a is a virulence factor involved in inflammatory pathology in cats.
    Antiviral Res. 2024;222:105794.
    PubMed     Abstract available
    
    
    January 2024
99. WINIGER RR, Perez L
    Therapeutic antibodies and alternative formats against SARS-CoV-2.
    Antiviral Res. 2024 Jan 31:105820. doi: 10.1016/j.antiviral.2024.105820.
    PubMed     Abstract available
    
    
    
100. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
     Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
     Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
     PubMed     Abstract available
     
     
     
101. BOGACHEVA MS, Kuivanen S, Potdar S, Hassinen A, et al
     Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
     Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813.
     PubMed     Abstract available
     
     
     
102. BOND ACS, Crocker MA, Wilczek MP, DuShane JK, et al
     High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection.
     Antiviral Res. 2024 Jan 19:105817. doi: 10.1016/j.antiviral.2024.105817.
     PubMed     Abstract available
     
     
     
103. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
     An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
     Antiviral Res. 2024;222:105815.
     PubMed     Abstract available
     
     
     
104. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al
     TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
     Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
     PubMed     Abstract available
     
     
     
105. GARCIA-RODRIGUEZ I, Moreni G, Capendale PE, Mulder L, et al
     Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.
     Antiviral Res. 2024 Jan 6:105798. doi: 10.1016/j.antiviral.2024.105798.
     PubMed     Abstract available
     
     
     December 2023
106. CHEN X, Tian L, Zhang L, Gao W, et al
     Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope protein.
     Antiviral Res. 2023;221:105790.
     PubMed     Abstract available
     
     
     
107. DOIJEN J, Heo I, Temmerman K, Vermeulen P, et al
     A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects.
     Antiviral Res. 2023 Dec 27:105789. doi: 10.1016/j.antiviral.2023.105789.
     PubMed     Abstract available
     
     
     
108. AKSU M, Kumar P, Guttler T, Taxer W, et al
     Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
     Antiviral Res. 2023 Dec 6:105778. doi: 10.1016/j.antiviral.2023.105778.
     PubMed     Abstract available
     
     
     
109. WANGEN C, Raithel A, Tillmanns J, Gege C, et al
     Validation of nuclear receptor RORgamma isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels.
     Antiviral Res. 2023 Dec 4:105769. doi: 10.1016/j.antiviral.2023.105769.
     PubMed     Abstract available
     
     
     
110. ZUR M, Peselev T, Yanko S, Rotshild V, et al
     Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
     Antiviral Res. 2023 Dec 4:105768. doi: 10.1016/j.antiviral.2023.105768.
     PubMed     Abstract available
     
     
     
111. WANG S, Wang Z, Li Y, Tu S, et al
     Generation of whole-porcine neutralizing antibodies of an alphacoronavirus by single B cell antibody technology.
     Antiviral Res. 2023;220:105754.
     PubMed     Abstract available
     
     
     November 2023
112. GALLUCCI L, Bazire J, Davidson AD, Shytaj IL, et al
     Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro.
     Antiviral Res. 2023;221:105766.
     PubMed     Abstract available
     
     
     
113. WANG S, Cui H, Zhang C, Li W, et al
     Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters.
     Antiviral Res. 2023 Nov 28:105765. doi: 10.1016/j.antiviral.2023.105765.
     PubMed     Abstract available
     
     
     
114. FORRESTALL K, Pringle ES, Sands D, Duguay BA, et al
     A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition.
     Antiviral Res. 2023;220:105758.
     PubMed     Abstract available
     
     
     
115. SUBRAMANI C, Sharma G, Chaira T, Barman TK, et al
     High content screening strategies for large-scale compound libraries with a focus on high-containment viruses.
     Antiviral Res. 2023 Nov 24:105764. doi: 10.1016/j.antiviral.2023.105764.
     PubMed     Abstract available
     
     
     
116. GOMEZ-CARBALLA A, Albericio G, Montoto-Louzao J, Perez P, et al
     Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
     Antiviral Res. 2023 Nov 20:105760. doi: 10.1016/j.antiviral.2023.105760.
     PubMed     Abstract available
     
     
     
117. WU CY, Tseng YC, Kao SE, Wu LY, et al
     Monoglycosylated SARS-CoV-2 receptor binding domain fused with HA(stem)-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses.
     Antiviral Res. 2023 Nov 18:105759. doi: 10.1016/j.antiviral.2023.105759.
     PubMed     Abstract available
     
     
     
118. ZHANG QY, Zhang HQ, Zhang YN, Zhang ZR, et al
     Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
     Antiviral Res. 2023 Nov 18:105757. doi: 10.1016/j.antiviral.2023.105757.
     PubMed     Abstract available
     
     
     
119. CHUANG YT, Lin YL, Lin JY
     Licochalcone A regulates viral IRES activity to inhibit enterovirus replication.
     Antiviral Res. 2023 Nov 18:105755. doi: 10.1016/j.antiviral.2023.105755.
     PubMed     Abstract available
     
     
     
120. SADHU S, Dandotiya J, Dalal R, Khatri R, et al
     Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
     Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743.
     PubMed     Abstract available
     
     
     
121. HSIEH HC, Chen CC, Chou PH, Liu WC, et al
     Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
     Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752.
     PubMed     Abstract available
     
     
     
122. SU WC, Chen ZY, Chang YS, Jeng KS, et al
     Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization.
     Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744.
     PubMed     Abstract available
     
     
     
123. KIM DG, Kim U, Park IH, Ryu B, et al
     A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants.
     Antiviral Res. 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738.
     PubMed     Abstract available
     
     
     October 2023
124. DEMIAN WL, Jacob RA, Cormier O, Nazli A, et al
     ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2.
     Antiviral Res. 2023 Oct 18:105736. doi: 10.1016/j.antiviral.2023.105736.
     PubMed     Abstract available
     
     
     
125. PALLA SR, Li CW, Chao TL, Lo HV, et al
     Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors.
     Antiviral Res. 2023 Oct 17:105735. doi: 10.1016/j.antiviral.2023.105735.
     PubMed     Abstract available
     
     
     
126. KONKEL R, Milewska A, Do NDT, Barreto Duran E, et al
     Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411.
     Antiviral Res. 2023 Oct 12:105731. doi: 10.1016/j.antiviral.2023.105731.
     PubMed     Abstract available
     
     
     
127. MAMATIS JE, Gallardo-Flores CE, Sangwan U, Tooley TH, et al
     Induction of antiviral gene expression by cyclosporine a, but not inhibition of cyclophilin a or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell line.
     Antiviral Res. 2023 Oct 5:105730. doi: 10.1016/j.antiviral.2023.105730.
     PubMed     Abstract available
     
     
     September 2023
128. BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al
     Corrigendum to ' Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase' [Antiviral Research 218 (2023) 105716-105728/ doi: 10.1016/j.antiviral.2023.105716].
     Antiviral Res. 2023 Sep 28:105729. doi: 10.1016/j.antiviral.2023.105729.
     PubMed    
     
     
     
129. MCMILLAN RE, Lo MK, Zhang XQ, Beadle JR, et al
     Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs.
     Antiviral Res. 2023 Sep 25:105718. doi: 10.1016/j.antiviral.2023.105718.
     PubMed     Abstract available
     
     
     
130. BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al
     Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
     Antiviral Res. 2023 Sep 8:105716. doi: 10.1016/j.antiviral.2023.105716.
     PubMed     Abstract available
     
     
     
131. MARTIN HJ, Melo-Filho CC, Korn D, Eastman RT, et al
     Small molecule antiviral compound collection (SMACC): A comprehensive, highly curated database to support the discovery of broad-spectrum antiviral drug molecules.
     Antiviral Res. 2023;217:105620.
     PubMed     Abstract available
     
     
     August 2023
132. VANDERLINDEN E, Boonen A, Noppen S, Schoofs G, et al
     PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.
     Antiviral Res. 2023;217:105700.
     PubMed     Abstract available
     
     
     
133. CORONA A, Madia VN, De Santis R, Manelfi C, et al
     Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
     Antiviral Res. 2023;217:105697.
     PubMed     Abstract available
     
     
     July 2023
134. SPENGLER JR, Carter K, Delang L, Durantel D, et al
     Meeting report: 36th international conference on antiviral research in Lyon, France, March 13-17, 2023.
     Antiviral Res. 2023 Jul 24:105678. doi: 10.1016/j.antiviral.2023.105678.
     PubMed     Abstract available
     
     
     
135. SUPREWICZ L, Szczepanski A, Lenart M, Piktel E, et al
     Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response.
     Antiviral Res. 2023 Jul 20:105676. doi: 10.1016/j.antiviral.2023.105676.
     PubMed     Abstract available
     
     
     
136. BOWDEN-REID E, Ledger S, Zhang Y, Di Giallonardo F, et al
     Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
     Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677.
     PubMed     Abstract available
     
     
     
137. LI Y, Wang Y, Li Y, de Vries AC, et al
     Seasonal coronavirus infections trigger NLRP3 inflammasome activation in macrophages but is therapeutically targetable.
     Antiviral Res. 2023 Jul 15:105674. doi: 10.1016/j.antiviral.2023.105674.
     PubMed     Abstract available
     
     
     
138. TAKASHITA E, Fujisaki S, Morita H, Nagata S, et al
     Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
     Antiviral Res. 2023;216:105671.
     PubMed     Abstract available
     
     
     
139. JEONG JH, Choi JH, Kim BK, Min SC, et al
     Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses.
     Antiviral Res. 2023 Jul 10:105669. doi: 10.1016/j.antiviral.2023.105669.
     PubMed     Abstract available
     
     
     
140. FENG Y, Yang Y, Zou S, Qiu S, et al
     Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
     Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666.
     PubMed     Abstract available
     
     
     June 2023
141. CAI H, Yan J, Liu S, Li P, et al
     Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.
     Antiviral Res. 2023 Jun 25:105659. doi: 10.1016/j.antiviral.2023.105659.
     PubMed     Abstract available
     
     
     
142. MILAN BONOTTO R, Mitrovic A, Sosic I, Martinez-Orellana P, et al
     Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection.
     Antiviral Res. 2023;216:105655.
     PubMed     Abstract available
     
     
     
143. JUNG HE, Ku KB, Kang BH, Park JH, et al
     Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
     Antiviral Res. 2023;216:105656.
     PubMed     Abstract available
     
     
     
144. CHANG YJ, Le UNP, Liu JJ, Li SR, et al
     Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
     Antiviral Res. 2023 Jun 13:105653. doi: 10.1016/j.antiviral.2023.105653.
     PubMed     Abstract available
     
     
     May 2023
145. DRIOUICH JS, Bernadin O, Touret F, de Lamballerie X, et al
     Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
     Antiviral Res. 2023 May 17:105638. doi: 10.1016/j.antiviral.2023.105638.
     PubMed     Abstract available
     
     
     
146. HUANG X, Fan W, Sun J, Yang J, et al
     SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril.
     Antiviral Res. 2023 May 17:105636. doi: 10.1016/j.antiviral.2023.105636.
     PubMed     Abstract available
     
     
     April 2023
147. CHO J, Shin Y, Yang JS, Kim JW, et al
     Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
     Antiviral Res. 2023;214:105609.
     PubMed     Abstract available
     
     
     
148. LI Y, Wang K, Sun H, Wu S, et al
     Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
     Antiviral Res. 2023 Apr 17:105606. doi: 10.1016/j.antiviral.2023.105606.
     PubMed     Abstract available
     
     
     
149. CONG Y, Lee JH, Perry DL, Cooper K, et al
     Longitudinal analyses using (18)F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.
     Antiviral Res. 2023 Apr 15:105605. doi: 10.1016/j.antiviral.2023.105605.
     PubMed     Abstract available
     
     
     March 2023
150. BILLS C, Xie X, Shi PY
     The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2.
     Antiviral Res. 2023;213:105590.
     PubMed     Abstract available
     
     
     
151. CONG Y, Mucker EM, Perry DL, Dixit S, et al
     Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
     Antiviral Res. 2023;213:105589.
     PubMed     Abstract available
     
     
     
152. PEREZ-VARGAS J, Shapira T, Olmstead AD, Villanueva I, et al
     Corrigendum to "Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics" "Antiviral Research 209 (2023)/105484".
     Antiviral Res. 2023 Mar 30:105577. doi: 10.1016/j.antiviral.2023.105577.
     PubMed    
     
     
     
153. YANG Y, Cao L, Yan M, Zhou J, et al
     Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
     Antiviral Res. 2023 Mar 28:105586. doi: 10.1016/j.antiviral.2023.105586.
     PubMed     Abstract available
     
     
     
154. VANHULLE E, Doijen J, Stroobants J, Provinciael B, et al
     Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants.
     Antiviral Res. 2023;213:105587.
     PubMed     Abstract available
     
     
     
155. DICHTL S, Diem G, Jager M, Zaderer V, et al
     Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation.
     Antiviral Res. 2023 Mar 23:105581. doi: 10.1016/j.antiviral.2023.105581.
     PubMed     Abstract available
     
     
     
156. ALVES RPDS, Wang YT, Mikulski Z, McArdle S, et al
     SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model.
     Antiviral Res. 2023 Mar 18:105580. doi: 10.1016/j.antiviral.2023.105580.
     PubMed     Abstract available
     
     
     
157. LIANG JQ, Xie MY, Hou L, Wang HL, et al
     miRNAs derived from milk small extracellular vesicles inhibit porcine epidemic diarrhea virus infection.
     Antiviral Res. 2023 Mar 10:105579. doi: 10.1016/j.antiviral.2023.105579.
     PubMed     Abstract available
     
     
     
158. LU C, Zhang Y, Liu X, Hou F, et al
     Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine.
     Antiviral Res. 2023;212:105556.
     PubMed     Abstract available
     
     
     
159. KIM JW, Heo K, Kim HJ, Yoo Y, et al
     Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
     Antiviral Res. 2023;212:105576.
     PubMed     Abstract available
     
     
     
160. SHEKUNOV EV, Zlodeeva PD, Efimova SS, Muryleva AA, et al
     Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.
     Antiviral Res. 2023;212:105575.
     PubMed     Abstract available
     
     
     
161. HU Y, Zhu Y, Yu Y, Liu N, et al
     Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
     Antiviral Res. 2023;212:105571.
     PubMed     Abstract available
     
     
     February 2023
162. ZHAO L, Yao L, Chen R, He J, et al
     Pinosrtobin from plants and propolis against human coronavirus HCoV-OC43 by modulating host AHR/CYP1A1 pathway and lipid metabolism.
     Antiviral Res. 2023 Feb 28:105570. doi: 10.1016/j.antiviral.2023.105570.
     PubMed     Abstract available
     
     
     
163. XIAO Y, Yan Y, Chang L, Ji H, et al
     CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation.
     Antiviral Res. 2023 Feb 18:105558. doi: 10.1016/j.antiviral.2023.105558.
     PubMed     Abstract available
     
     
     
164. LI J, Wang Y, Solanki K, Atre R, et al
     Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
     Antiviral Res. 2023 Feb 13:105555. doi: 10.1016/j.antiviral.2023.105555.
     PubMed     Abstract available
     
     
     
165. MERINO VF, Yan Y, Ordonez AA, Bullen CK, et al
     Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells.
     Antiviral Res. 2023;211:105550.
     PubMed     Abstract available
     
     
     
166. KURHADE C, Xie X, Shi PY
     Reverse genetic systems of SARS-CoV-2 for antiviral research.
     Antiviral Res. 2023;210:105486.
     PubMed     Abstract available
     
     
     January 2023
167. ZHU Y, Li M, Liu N, Wu T, et al
     Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.
     Antiviral Res. 2023;211:105541.
     PubMed     Abstract available
     
     
     
168. BASILE A, Zannella C, De Marco M, Sanna G, et al
     Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody.
     Antiviral Res. 2023;211:105546.
     PubMed     Abstract available
     
     
     December 2022
169. SPENGLER JR, Welch SR, Deval J, Gentry BG, et al
     Meeting report: 35th international conference on antiviral research in Seattle, WA, USA - March 21-25, 2022.
     Antiviral Res. 2022 Dec 31:105521. doi: 10.1016/j.antiviral.2022.105521.
     PubMed     Abstract available
     
     
     
170. CHISTOV AA, Chumakov SP, Mikhnovets IE, Nikitin TD, et al
     5-(Perylen-3-ylethynyl)uracil as an antiviral scaffold: Potent suppression of enveloped virus reproduction by 3-methyl derivatives in vitro.
     Antiviral Res. 2022 Dec 26:105508. doi: 10.1016/j.antiviral.2022.105508.
     PubMed     Abstract available
     
     
     
171. LIM SP
     Targeting SARS-CoV-2 and host cell receptor interactions.
     Antiviral Res. 2022 Dec 26:105514. doi: 10.1016/j.antiviral.2022.105514.
     PubMed     Abstract available
     
     
     
172. HU L, Tang Y, Mei L, Liang M, et al
     A new intracellular targeting motif in the cytoplasmic tail of the spike protein may act as a target to inhibit SARS-CoV-2 assembly.
     Antiviral Res. 2022;209:105509.
     PubMed     Abstract available
     
     
     
173. TNG DJH, Low JGH
     Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses.
     Antiviral Res. 2022 Dec 22:105488. doi: 10.1016/j.antiviral.2022.105488.
     PubMed     Abstract available
     
     
     
174. SHANNON A, Canard B
     Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2.
     Antiviral Res. 2022 Dec 21:105501. doi: 10.1016/j.antiviral.2022.105501.
     PubMed     Abstract available
     
     
     
175. CHIU W, Schepers J, Francken T, Vangeel L, et al
     Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.
     Antiviral Res. 2022 Dec 21:105506. doi: 10.1016/j.antiviral.2022.105506.
     PubMed     Abstract available
     
     
     
176. ZHANG YN, Zhang HQ, Wang GF, Zhang ZR, et al
     Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster.
     Antiviral Res. 2022;209:105507.
     PubMed     Abstract available
     
     
     
177. JOHNSON DM, Brasel T, Massey S, Garron T, et al
     Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
     Antiviral Res. 2022 Dec 16:105492. doi: 10.1016/j.antiviral.2022.105492.
     PubMed     Abstract available
     
     
     
178. PEREZ-VARGAS J, Shapira T, Olmstead AD, Villanueva I, et al
     Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
     Antiviral Res. 2022 Dec 8:105484. doi: 10.1016/j.antiviral.2022.105484.
     PubMed     Abstract available
     
     
     
179. HASHIZUME M, Takashima A, Ono C, Okamoto T, et al
     Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1.
     Antiviral Res. 2022 Dec 5:105481. doi: 10.1016/j.antiviral.2022.105481.
     PubMed     Abstract available
     
     
     
180. YAO Y, Sun H, Chen Y, Tian L, et al
     RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5'-untranslated region.
     Antiviral Res. 2022;209:105478.
     PubMed     Abstract available
     
     
     November 2022
181. JEONG K, Chang J, Park SM, Kim J, et al
     Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay.
     Antiviral Res. 2022 Nov 23:105473. doi: 10.1016/j.antiviral.2022.105473.
     PubMed     Abstract available
     
     
     
182. FAIST A, Schloer S, Mecate-Zambrano A, Janowski J, et al
     Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier.
     Antiviral Res. 2022 Nov 21:105475. doi: 10.1016/j.antiviral.2022.105475.
     PubMed     Abstract available
     
     
     
183. HUI X, Yu X, Huang K, Xu T, et al
     In vitro and in vivo effects of 3-indoleacetonitrile-A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection.
     Antiviral Res. 2022 Nov 16:105465. doi: 10.1016/j.antiviral.2022.105465.
     PubMed     Abstract available
     
     
     
184. FABREGA-FERRER M, Herrera-Morande A, Muriel-Goni S, Perez-Saavedra J, et al
     Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404.
     Antiviral Res. 2022;208:105458.
     PubMed     Abstract available
     
     
     
185. ZENG Y, Song F, Luo G, Yang H, et al
     Generation and characterization of mouse monoclonal antibodies against the VP4 protein of group A human rotaviruses.
     Antiviral Res. 2022;207:105407.
     PubMed     Abstract available
     
     
     October 2022
186. ZHANG T, Su S, Altouma V, Zhu X, et al
     Topoisomerase 3b is dispensable for replication of a positive-sense RNA virus--murine coronavirus.
     Antiviral Res. 2022 Oct 31:105451. doi: 10.1016/j.antiviral.2022.105451.
     PubMed     Abstract available
     
     
     
187. VARRICCHIO C, Mathez G, Pillonel T, Bertelli C, et al
     Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifting.
     Antiviral Res. 2022;208:105452.
     PubMed     Abstract available
     
     
     
188. SHANG W, Dai W, Yao C, Xu L, et al
     In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2.
     Antiviral Res. 2022;208:105450.
     PubMed     Abstract available
     
     
     
189. ZHU Y, Hu Y, Liu N, Chong H, et al
     Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
     Antiviral Res. 2022;208:105445.
     PubMed     Abstract available
     
     
     
190. KIM TY, Kim JY, Kwon HC, Jeon S, et al
     Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibit the infection of SARS-CoV-2 variants and syncytium formation.
     Antiviral Res. 2022 Oct 14:105428. doi: 10.1016/j.antiviral.2022.105428.
     PubMed     Abstract available
     
     
     
191. BRAY M
     Antiviral Research: At age 41, a transition.
     Antiviral Res. 2022 Oct 14:105447. doi: 10.1016/j.antiviral.2022.105447.
     PubMed     Abstract available
     
     
     
192. JEONG JH, Chokkakula S, Min SC, Kim BK, et al
     Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
     Antiviral Res. 2022;208:105430.
     PubMed     Abstract available
     
     
     
193. ZHU Y, Binder J, Yurgelonis I, Rai D, et al
     Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study.
     Antiviral Res. 2022 Oct 5:105429. doi: 10.1016/j.antiviral.2022.105429.
     PubMed     Abstract available
     
     
     September 2022
194. MA L, Li Q, Xie Y, Jianyuan Zhao, et al
     Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro).
     Antiviral Res. 2022 Sep 22:105419. doi: 10.1016/j.antiviral.2022.105419.
     PubMed     Abstract available
     
     
     August 2022
195. DEMAREST JF, Kienle M, Boytz R, Ayres M, et al
     Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
     Antiviral Res. 2022 Aug 27:105403. doi: 10.1016/j.antiviral.2022.105403.
     PubMed     Abstract available
     
     
     
196. LAI M, De Carli A, Filipponi C, Iacono E, et al
     Lipid balance remodelling by human positive-strand RNA viruses and the contribution of lysosomes.
     Antiviral Res. 2022 Aug 17:105398. doi: 10.1016/j.antiviral.2022.105398.
     PubMed     Abstract available
     
     
     
197. LU L, Peng Y, Yao H, Wang Y, et al
     Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro.
     Antiviral Res. 2022 Aug 16:105389. doi: 10.1016/j.antiviral.2022.105389.
     PubMed     Abstract available
     
     
     July 2022
198. LI M, Chen J, Liu Y, Zhao J, et al
     Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants.
     Antiviral Res. 2022 Jul 30:105383. doi: 10.1016/j.antiviral.2022.105383.
     PubMed     Abstract available
     
     
     
199. SAMRAT SK, Xu J, Xie X, Gianti E, et al
     Allosteric inhibitors of the main protease of SARS-CoV-2.
     Antiviral Res. 2022;205:105381.
     PubMed     Abstract available
     
     
     
200. BEZERRA BB, Silva GPDD, Antunes Coelho SV, Correa IA, et al
     Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines.
     Antiviral Res. 2022 Jul 4:105373. doi: 10.1016/j.antiviral.2022.105373.
     PubMed     Abstract available
     
     
     
201. OHASHI H, Hishiki T, Akazawa D, Kim KS, et al
     Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
     Antiviral Res. 2022 Jul 4:105372. doi: 10.1016/j.antiviral.2022.105372.
     PubMed     Abstract available
     
     
     June 2022
202. KIM EH, Lee BW, Ryu B, Cho HM, et al
     Inhibition of a broad range of SARS-CoV-2 variants by antiviral phytochemicals in hACE2 mice.
     Antiviral Res. 2022;204:105371.
     PubMed     Abstract available
     
     
     
203. SEEPHETDEE C, Bhukhai K, Buasri N, Leelukkanaveera P, et al
     A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
     Antiviral Res. 2022 Jun 27:105370. doi: 10.1016/j.antiviral.2022.105370.
     PubMed     Abstract available
     
     
     
204. KARIM M, Saul S, Ghita L, Sahoo MK, et al
     Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies.
     Antiviral Res. 2022 Jun 20:105367. doi: 10.1016/j.antiviral.2022.105367.
     PubMed     Abstract available
     
     
     
205. ZHOU M, Liu Y, Cao J, Dong S, et al
     Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters.
     Antiviral Res. 2022 Jun 19:105365. doi: 10.1016/j.antiviral.2022.105365.
     PubMed     Abstract available
     
     
     
206. HERNANDEZ S, Feracci M, De Jesus CT, El Kazzi P, et al
     Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay.
     Antiviral Res. 2022 Jun 15:105364. doi: 10.1016/j.antiviral.2022.105364.
     PubMed     Abstract available
     
     
     
207. MELO-FILHO CC, Bobrowski T, Martin HJ, Sessions Z, et al
     Conserved coronavirus proteins as targets of broad-spectrum antivirals.
     Antiviral Res. 2022 Jun 9:105360. doi: 10.1016/j.antiviral.2022.105360.
     PubMed     Abstract available
     
     
     
208. MERCORELLI B, Desantis J, Celegato M, Bazzacco A, et al
     Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization.
     Antiviral Res. 2022;204:105350.
     PubMed     Abstract available
     
     
     May 2022
209. PRASHAR P, Swain S, Adhikari N, Aryan P, et al
     A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies.
     Antiviral Res. 2022 May 28:105349. doi: 10.1016/j.antiviral.2022.105349.
     PubMed     Abstract available
     
     
     
210. LIN Q, Lu C, Hong Y, Li R, et al
     Animal models for studying coronavirus infections and developing antiviral agents and vaccines.
     Antiviral Res. 2022 May 20:105345. doi: 10.1016/j.antiviral.2022.105345.
     PubMed     Abstract available
     
     
     
211. ROY A, Alhammad YM, McDonald P, Johnson DK, et al
     Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
     Antiviral Res. 2022 May 19:105344. doi: 10.1016/j.antiviral.2022.105344.
     PubMed     Abstract available
     
     
     
212. WEIL T, Lawrenz J, Seidel A, Munch J, et al
     Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor.
     Antiviral Res. 2022 May 19:105343. doi: 10.1016/j.antiviral.2022.105343.
     PubMed     Abstract available
     
     
     
213. VANHULLE E, Stroobants J, Provinciael B, Camps A, et al
     SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening.
     Antiviral Res. 2022 May 17:105342. doi: 10.1016/j.antiviral.2022.105342.
     PubMed     Abstract available
     
     
     
214. FINDLAY-WILSON S, Easterbrook L, Smith S, Pope N, et al
     Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.
     Antiviral Res. 2022 May 6:105332. doi: 10.1016/j.antiviral.2022.105332.
     PubMed     Abstract available
     
     
     
215. PITTS J, Babusis D, Vermillion MS, Subramanian R, et al
     Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
     Antiviral Res. 2022 May 4:105329. doi: 10.1016/j.antiviral.2022.105329.
     PubMed     Abstract available
     
     
     April 2022
216. FOO CS, Abdelnabi R, Kaptein SJF, Zhang X, et al
     HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
     Antiviral Res. 2022;202:105311.
     PubMed     Abstract available
     
     
     
217. VANMECHELEN B, Stroobants J, Chiu W, Schepers J, et al
     Identification of novel Ebola virus inhibitors using biologically contained virus.
     Antiviral Res. 2022;200:105294.
     PubMed     Abstract available
     
     
     March 2022
218. UENO M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, et al
     Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
     Antiviral Res. 2022;201:105297.
     PubMed     Abstract available
     
     
     
219. LAI GC, Chao TL, Lin SY, Kao HC, et al
     Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.
     Antiviral Res. 2022;200:105290.
     PubMed     Abstract available
     
     
     
220. PASQUERO S, Gugliesi F, Griffante G, Dell'Oste V, et al
     Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2.
     Antiviral Res. 2022;200:105278.
     PubMed     Abstract available
     
     
     
221. CHEN KY, Krischuns T, Varga LO, Harigua-Souiai E, et al
     A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
     Antiviral Res. 2022 Mar 9:105272. doi: 10.1016/j.antiviral.2022.105272.
     PubMed     Abstract available
     
     
     
222. SCHOLLE MD, O'Kane PT, Dib S, Gurard-Levin ZA, et al
     Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors.
     Antiviral Res. 2022;200:105279.
     PubMed     Abstract available
     
     
     
223. TANAKA T, Saito A, Suzuki T, Miyamoto Y, et al
     Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening.
     Antiviral Res. 2022;199:105268.
     PubMed     Abstract available
     
     
     February 2022
224. TSAI TI, Khalili JS, Gilchrist M, Waight AB, et al
     ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern.
     Antiviral Res. 2022 Feb 28:105271. doi: 10.1016/j.antiviral.2022.105271.
     PubMed     Abstract available
     
     
     
225. SACHSE M, Tenorio R, Fernandez de Castro I, Munoz-Basagoiti J, et al
     Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis.
     Antiviral Res. 2022 Feb 26:105270. doi: 10.1016/j.antiviral.2022.105270.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO COVID-19 is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum